AU743823B2 - Radioprotectant for peptides labeled with radioisotope - Google Patents

Radioprotectant for peptides labeled with radioisotope Download PDF

Info

Publication number
AU743823B2
AU743823B2 AU80570/98A AU8057098A AU743823B2 AU 743823 B2 AU743823 B2 AU 743823B2 AU 80570/98 A AU80570/98 A AU 80570/98A AU 8057098 A AU8057098 A AU 8057098A AU 743823 B2 AU743823 B2 AU 743823B2
Authority
AU
Australia
Prior art keywords
composition
radiolabeled
povidone
peptide
mci
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU80570/98A
Other languages
English (en)
Other versions
AU8057098A (en
Inventor
Michael J. Buckley
Albert S. K. Chan
David Colcher
Dan Shochat
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Coulter Pharmaceutical Inc
Original Assignee
Coulter Pharmaceutical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Coulter Pharmaceutical Inc filed Critical Coulter Pharmaceutical Inc
Publication of AU8057098A publication Critical patent/AU8057098A/en
Application granted granted Critical
Publication of AU743823B2 publication Critical patent/AU743823B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU80570/98A 1997-06-03 1998-06-03 Radioprotectant for peptides labeled with radioisotope Ceased AU743823B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US4838797P 1997-06-03 1997-06-03
US60/048387 1997-06-03
US08/918,525 US5961955A (en) 1997-06-03 1997-08-21 Radioprotectant for peptides labeled with radioisotope
US08/918525 1997-08-21
PCT/US1998/011428 WO1998055154A1 (en) 1997-06-03 1998-06-03 Radioprotectant for peptides labeled with radioisotope

Publications (2)

Publication Number Publication Date
AU8057098A AU8057098A (en) 1998-12-21
AU743823B2 true AU743823B2 (en) 2002-02-07

Family

ID=26726075

Family Applications (1)

Application Number Title Priority Date Filing Date
AU80570/98A Ceased AU743823B2 (en) 1997-06-03 1998-06-03 Radioprotectant for peptides labeled with radioisotope

Country Status (14)

Country Link
US (2) US5961955A (OSRAM)
EP (1) EP1003560B1 (OSRAM)
JP (1) JP4291417B2 (OSRAM)
AT (1) ATE249845T1 (OSRAM)
AU (1) AU743823B2 (OSRAM)
CA (1) CA2290987A1 (OSRAM)
DE (1) DE69818272T2 (OSRAM)
DK (1) DK1003560T3 (OSRAM)
ES (1) ES2212304T3 (OSRAM)
IL (1) IL133271A (OSRAM)
NO (1) NO315693B1 (OSRAM)
NZ (1) NZ502029A (OSRAM)
PT (1) PT1003560E (OSRAM)
WO (1) WO1998055154A1 (OSRAM)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5961955A (en) * 1997-06-03 1999-10-05 Coulter Pharmaceutical, Inc. Radioprotectant for peptides labeled with radioisotope
WO1999062564A1 (en) * 1998-06-02 1999-12-09 The Dow Chemical Company Radioiodinated phenols for brachytherapy
US20020102208A1 (en) * 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
KR100330733B1 (ko) * 1999-11-30 2002-04-03 노광 폴리에틸렌글리콜포스페이트, 그의 합성방법 및 그를방사능보호제로 사용하는 방법
AU2002211232B2 (en) * 2000-09-15 2006-10-19 Sloan Kettering Institute For Cancer Research Targeted alpha particle therapy using actinium-225 conjugates
CZ20032597A3 (cs) * 2001-02-26 2004-12-15 Bristol-Myers Squibb Pharma Company Analogy kyseliny askorbové pro metaloradiofarmaceutika
US6972324B2 (en) * 2001-05-18 2005-12-06 Boehringer Ingelheim Pharmaceuticals, Inc. Antibodies specific for CD44v6
US7238338B1 (en) * 2001-06-22 2007-07-03 Triumf System and method for the large scale labeling of compounds with radiohalogens
US7344702B2 (en) 2004-02-13 2008-03-18 Bristol-Myers Squibb Pharma Company Contrast agents for myocardial perfusion imaging
WO2003105762A2 (en) * 2002-06-14 2003-12-24 Actinium Pharmaceuticals Ltd. Treating disease using radium-225
US7018614B2 (en) * 2002-11-05 2006-03-28 Eastern Isotopes, Inc. Stabilization of radiopharmaceuticals labeled with 18-F
EP1575516B1 (en) 2002-11-26 2012-05-30 Abbott Biotherapeutics Corp. Chimeric and humanized antibodies to alpha5 beta1 integrin that modulate angiogenesis
EP1444990A1 (en) * 2003-02-07 2004-08-11 Amersham plc Improved Radiometal Complex Compositions
US7485283B2 (en) * 2004-04-28 2009-02-03 Lantheus Medical Imaging Contrast agents for myocardial perfusion imaging
WO2006020060A2 (en) 2004-07-15 2006-02-23 Tetralogic Pharmaceuticals Corporation Iap binding compounds
DK1851200T3 (da) 2005-02-25 2014-04-14 Tetralogic Pharm Corp Dimere iap-inhibitorer
JP2009509128A (ja) * 2005-08-09 2009-03-05 テトラロジック ファーマシューティカルズ コーポレーション 増殖性疾患の治療
US20100256046A1 (en) * 2009-04-03 2010-10-07 Tetralogic Pharmaceuticals Corporation Treatment of proliferative disorders
US20100056495A1 (en) * 2006-07-24 2010-03-04 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
WO2008014238A2 (en) * 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
CL2007002167A1 (es) * 2006-07-24 2009-01-23 Tetralogic Pharm Corp Compuestos derivados de indol, antagonistas iap; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de cancer.
JP5452223B2 (ja) * 2006-07-24 2014-03-26 テトラロジック ファーマシューティカルズ コーポレーション Ｉａｐ阻害剤
WO2008014240A2 (en) * 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
KR101408680B1 (ko) 2007-01-26 2014-06-17 가부시키가이샤 폴라 파마 의약 조성물
US8367052B2 (en) 2007-03-26 2013-02-05 General Regeneratives Holdings Inc. Methods for promoting protection and regeneration of bone marrow using CXCL9 and anti-CXCL9 antibodies
WO2009110984A2 (en) * 2008-02-29 2009-09-11 Lantheus Medical Imaging, Inc. Contrast agents for applications including perfusion imaging
RU2011124527A (ru) * 2008-11-17 2012-12-27 Дженентек, Инк. Способ и композиция для уменьшения агрегации макромолекулы в физиологических условиях
ES2770364T3 (es) 2009-04-15 2020-07-01 Lantheus Medical Imaging Inc Estabilización de composiciones radiofarmacéuticas utilizando ácido ascórbico
US8283372B2 (en) * 2009-07-02 2012-10-09 Tetralogic Pharmaceuticals Corp. 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic
RU2631500C2 (ru) 2010-02-08 2017-09-25 Лантеус Медикал Имаджинг, Инк. Способы и устройство для синтезирования радиофармацевтических препаратов и их промежуточных продуктов
GB201013808D0 (en) * 2010-08-18 2010-09-29 Ge Healthcare Ltd Peptide radiotracer compositions
AU2013203000B9 (en) 2012-08-10 2017-02-02 Lantheus Medical Imaging, Inc. Compositions, methods, and systems for the synthesis and use of imaging agents
CN105377287A (zh) * 2013-02-15 2016-03-02 托马斯杰弗逊大学 用于肿瘤成像的试剂盒
GB201314936D0 (en) 2013-08-21 2013-10-02 Ge Healthcare Ltd Radiolabelling method
GB201322456D0 (en) 2013-12-18 2014-02-05 Ge Healthcare Ltd Radiotracer compositions and methods
WO2015109246A1 (en) * 2014-01-17 2015-07-23 Repligen Corporation Sterilizing chromatography columns
IL237852A0 (en) 2015-03-19 2016-03-24 Yeda Res & Dev Antibodies against amphigoline, medical preparations containing them and their use
TWI799366B (zh) * 2015-09-15 2023-04-21 美商建南德克公司 胱胺酸結骨架平臺
HUE071169T2 (hu) * 2016-03-07 2025-08-28 Actinium Pharmaceuticals Inc Stabilizált, radioaktívan jelölt anti-CD45 immunglobulin-készítmények
WO2019089544A1 (en) 2017-11-01 2019-05-09 Tufts Medical Center, Inc. Bispecific antibody constructs and methods of use
US12599669B2 (en) 2019-04-23 2026-04-14 Amgen Inc. Use of low molecular weight polyvinylpyrrolidone (PVP) to reduce viscosity of high concentration protein formulations
US12043671B2 (en) 2021-06-16 2024-07-23 Gundersen Lutheran Medical Foundation, Inc. Antibodies targeting an amphiregulin-derived cell surface neo-epitope
CN121532218A (zh) 2023-06-16 2026-02-13 普罗热尼奇制药公司 前列腺特异性膜抗原（psma）放射性标记抑制剂[18f]dcfpyl的改进的合成

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE933885C (de) * 1952-06-22 1955-10-06 Helmut Richard Dr Kanitz Verfahren zur Herstellung kolloidaler Loesungen radioaktiver Metalle wie radioaktiver Goldisotope
US4421735A (en) * 1980-04-17 1983-12-20 The Massachusetts General Hospital Radiolabeled diagnostic compositions and method for making the same
US4427631A (en) * 1982-05-27 1984-01-24 Euroceltique, S.A. Povidone irradiation
US4411881A (en) * 1982-07-12 1983-10-25 New England Nuclear Corporation Composition and method for stabilizing radiolabeled compounds using thiocarbonylated diethylenetriamines
EP0111414A3 (en) * 1982-12-08 1985-05-02 Mallinckrodt, Inc. (a Delaware corporation) Radiographic imaging agents
US4676979A (en) * 1984-12-31 1987-06-30 Eastern Virginia Medical Authority/Med. Ctr. Hosp. Method of protecting animals against ionizing radiation
US5393512A (en) * 1985-01-14 1995-02-28 Vanderheyden; Jean-Luc Stable therapeutic radionuclide compositions and methods for preparation thereof
US5061641A (en) * 1988-04-01 1991-10-29 Immunomedics, Inc. Method for radiolabeling proteins
RO103925B1 (ro) * 1989-02-27 1992-04-26 Institutul De Chimie Macromoleculara "P.Poni" Derivat de polivinilpirolidona si procedeu de preparare
JPH05502219A (ja) * 1989-09-22 1993-04-22 ネオルクス　コーポレイション 安定な治療用放射性核種およびそれを調製する方法
US5011676A (en) * 1990-03-27 1991-04-30 Thomas Jefferson University Method to directly radiolabel antibodies for diagnostic imaging and therapy
AU2541592A (en) * 1991-08-01 1993-03-02 Hybritech Incorporated Improvements in or relating to modified haptens useful as imaging and therapeutic agents
ES2150916T3 (es) * 1991-08-29 2000-12-16 Mallinckrodt Medical Inc Utilizacion del acido gentisico o del alcohol gentisilico para estabilizar peptidos y proteinas radiomarcados.
CA2105402C (en) * 1992-04-30 2000-04-04 Roger M. Price Radiolabelled compound formulations
EP0622082A4 (en) * 1992-07-28 1996-12-04 Toray Industries IMMUNE COMPLEX.
US5595721A (en) * 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
US5961955A (en) * 1997-06-03 1999-10-05 Coulter Pharmaceutical, Inc. Radioprotectant for peptides labeled with radioisotope

Also Published As

Publication number Publication date
EP1003560B1 (en) 2003-09-17
JP2002516612A (ja) 2002-06-04
AU8057098A (en) 1998-12-21
DE69818272D1 (de) 2003-10-23
NZ502029A (en) 2001-12-21
NO995906D0 (no) 1999-12-02
DK1003560T3 (da) 2003-12-01
DE69818272T2 (de) 2004-07-01
NO995906L (no) 1999-12-03
ATE249845T1 (de) 2003-10-15
CA2290987A1 (en) 1998-12-10
NO315693B1 (no) 2003-10-13
US6338835B1 (en) 2002-01-15
ES2212304T3 (es) 2004-07-16
EP1003560A1 (en) 2000-05-31
WO1998055154A9 (en) 1999-04-08
PT1003560E (pt) 2004-02-27
IL133271A (en) 2004-06-01
IL133271A0 (en) 2001-04-30
JP4291417B2 (ja) 2009-07-08
WO1998055154A1 (en) 1998-12-10
US5961955A (en) 1999-10-05

Similar Documents

Publication Publication Date Title
EP1003560B1 (en) Radioprotectant for peptides labeled with radioisotope
TWI283178B (en) Method and kit for efficient radiolabeling of proteins with therapeutic radioisotopes
AU656915B2 (en) Stabilized therapeutic radiopharmaceutical complexes
EP0670736B1 (en) Labelled interleukin-8 and medical uses thereof
CA2279349C (en) Ascorbate-stabilized radiopharmaceutical method and composition
US4401647A (en) Radiolabeled neoglycopeptides
US6066309A (en) Post-labeling stabilization of radiolabeled proteins and peptides
Callahan et al. Preclinical evaluation and phase I clinical trial of a 99mTc-labeled synthetic polymer used in blood pool imaging.
WO1997028181A9 (en) Post-labeling stabilization of radiolabeled proteins and peptides
US20040120892A1 (en) Post-labeling stabilization of radiolabeled proteins and peptides
DeNardo et al. Are radiometal-labeled antibodies better than iodine-131–labeled antibodies: comparative pharmacokinetics and dosimetry of copper-67–, iodine-131–, and yttrium-90–labeled Lym-1 antibody in patients with non-Hodgkin's lymphoma
US20100047167A1 (en) Combination therapy in the treatment of cancer
KR101274867B1 (ko) 연조직 질환의 방사선 치료에 사용하기 위한 토륨-227
KR20050086907A (ko) 3중 작용 시약에 의해 연결된 작동성 및 친화성 기능을갖는 항림프종 표적화제
Gano et al. Human polyclonal immunoglobulin labelled with technetium-99m via NHS-MAG3: a comparison of radiochemical behavior and biological efficacy with other labelling methods
Singh et al. A simplified kit for instant preparation of technerium-99m human immunoglobulin-G for imaging inflammatory foci
Reynolds et al. Radiohalogenation of monoclonal antibodies: Experiences with radioiodination of monoclonal antibodies for radioimmunotherapy
Mills et al. Radiopharmaceutical preparation of a monoclonal antibody, lym‐1, and its F (ab') 2 fragment for imaging lymphoma with In‐111
Proulx et al. A kit for labelling erythrocytes or leukocytes with technetium-99m
Broer et al. 89Zr-brentuximab development for whole-body PET imaging of patients with CD30 positive lymphoma, eligible for brentuximab-vedotin therapy
Thu et al. Study On The Labeling Of Anti CD20 Monoclonal Antibody With I-131 For Blood Cancer Therapy
Akgun et al. Radiopharmaceuticals and their quality control

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)